ArticleChinese medicine2026
Mechanism of Qiling Fuzheng Qingjie granules in alleviating doxorubicin-induced T cell immune dysfunction via mitochondrial energy metabolism.
Article in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
This study investigates the mechanism by which Qiling Fuzheng Qingjie Granule (QFQ) regulates immune function following doxorubicin (DOX) chemotherapy. Network pharmacology analysis was employed to explore the relationship between QFQ and the immune system. A mouse model of DOX-induced immune dysfunction was established and treated with QFQ. Techniques including histological staining, peripheral complete blood count analysis, flow cytometry, and seahorse metabolic analysis were used to systematically evaluate the effects of QFQ on immune organs, bone marrow hematopoiesis, T-cell subset distribution and function, mitochondrial metabolism, and antitumor efficacy. The results demonstrated that QFQ significantly alleviated DOX-induced atrophy of the thymus and spleen, preserved bone marrow hematopoietic function, and reduced peripheral blood cell loss. Mechanistically, QFQ improved mitochondrial membrane potential and oxidative phosphorylation, thereby restoring T-cell metabolic capacity, enhancing T-cell activation and proliferation, and restoring cytotoxic T lymphocyte (CTL) function. Consequently, QFQ rebalanced the dynamics among Th1/Th2/Th17/Treg, Effector Memory T/Effector T cells (Tem/Teff), and Central Memory T cells (Tcm) subsets, ameliorated DOX-induced immune dysregulation. In addition, QFQ intervention not only enhanced antitumor efficacy in the A20 lymphoma mouse model but also significantly alleviated the exhaustion phenotype in CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.